Literature DB >> 20952555

Cohort mortality study of workers at seven beryllium processing plants: update and associations with cumulative and maximum exposure.

Mary K Schubauer-Berigan1, James R Couch, Martin R Petersen, Tania Carreón, Yan Jin, James A Deddens.   

Abstract

OBJECTIVES: To extend follow-up of cause-specific mortality in workers at seven beryllium processing plants and to estimate associations between mortality risk and beryllium exposure.
METHODS: 9199 workers were followed for mortality from 1940 through 2005. Standardised mortality ratios (SMRs) were estimated based on US population comparisons for lung, nervous system and urinary tract cancers, chronic obstructive pulmonary disease (COPD), chronic kidney disease, and categories containing chronic beryllium disease (CBD) and cor pulmonale. Associations with maximum and cumulative exposure were calculated for a subset of the workers.
RESULTS: Overall mortality in the cohort compared with the US population was elevated for lung cancer (SMR 1.17; 95% CI 1.08 to 1.28), COPD (SMR 1.23; 95% CI 1.13 to 1.32), and the categories containing CBD (SMR 7.80; 95% CI 6.26 to 9.60) and cor pulmonale (SMR 1.17; 95% CI 1.08 to 1.26). Mortality rates for most diseases of interest increased with time-since-hire. For the category including CBD, rates were substantially elevated compared to the US population across all exposure groups. Workers whose maximum beryllium exposure was ≥ 10 μg/m(3) had higher rates of lung cancer, urinary tract cancer, COPD and the category containing cor pulmonale than workers with lower exposure. Significant positive trends with cumulative exposure were observed for nervous system cancers (p = 0.0006) and, when short-term workers were excluded, lung cancer (p = 0.01), urinary tract cancer (p = 0.003) and COPD (p < 0.0001).
CONCLUSION: These findings reaffirm that lung cancer and CBD, and suggest that COPD and nervous system and urinary tract cancers, are related to beryllium exposure. Cigarette smoking and exposure to other lung carcinogens are unlikely to explain these elevations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952555     DOI: 10.1136/oem.2010.056481

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  7 in total

1.  HLA-DPB1 E69 genotype and exposure in beryllium sensitisation and disease.

Authors:  James Crooks; Margaret M Mroz; Michael VanDyke; Alison McGrath; Christine Schuler; Erin C McCanlies; M Abbas Virji; Kenneth D Rosenman; Milton Rossman; Carol Rice; Dimitri Monos; Tasha E Fingerlin; Lisa A Maier
Journal:  Occup Environ Med       Date:  2021-09-17       Impact factor: 4.402

Review 2.  Occupational and environmental causes of lung cancer.

Authors:  R William Field; Brian L Withers
Journal:  Clin Chest Med       Date:  2012-12       Impact factor: 2.878

3.  Occupational Cohort Time Scales.

Authors:  David C Deubner; H Daniel Roth
Journal:  J Occup Environ Med       Date:  2015-06       Impact factor: 2.162

4.  Bias from using occupational smoking prevalence to adjust occupational incidence cohort lung cancer mortality rates.

Authors:  David C Deubner; H Daniel Roth
Journal:  J Occup Environ Med       Date:  2015-02       Impact factor: 2.162

5.  A mortality study of beryllium workers.

Authors:  Paolo Boffetta; Tiffani A Fordyce; Jack S Mandel
Journal:  Cancer Med       Date:  2016-10-20       Impact factor: 4.452

6.  Carbon nanotube dosimetry: from workplace exposure assessment to inhalation toxicology.

Authors:  Aaron Erdely; Matthew Dahm; Bean T Chen; Patti C Zeidler-Erdely; Joseph E Fernback; M Eileen Birch; Douglas E Evans; Michael L Kashon; James A Deddens; Tracy Hulderman; Suzan A Bilgesu; Lori Battelli; Diane Schwegler-Berry; Howard D Leonard; Walter McKinney; David G Frazer; James M Antonini; Dale W Porter; Vincent Castranova; Mary K Schubauer-Berigan
Journal:  Part Fibre Toxicol       Date:  2013-10-21       Impact factor: 9.400

7.  A mortality study of workers exposed to insoluble forms of beryllium.

Authors:  Paolo Boffetta; Tiffani Fordyce; Jack S Mandel
Journal:  Eur J Cancer Prev       Date:  2014-11       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.